Lv5
1430 积分 2021-05-26 加入
Semaglutide and tirzepatide in prediabetes: Evidence for diabetes prevention and cardiovascular protection
11小时前
待确认
Staging prediabetes and type 2 diabetes: the time to start is now
8天前
已完结
Prediabetes remission for type 2 diabetes mellitus prevention
8天前
已完结
糖尿病前期治未病干预指南
8天前
已完结
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double‑blind, placebo‑controlled trial
14天前
已关闭
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
24天前
已完结
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
24天前
已完结
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial
24天前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
24天前
已完结
Patent landscape and therapeutic evolution of Mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes
1个月前
已完结
皖公网安备34019202002308
